缬沙坦联合美托洛尔对冠心病患者血液流变学研究

Study on hemorheology of valsartan combined with metoprolol in patients with coronary heart disease

目的探讨缬沙坦联合美托洛尔对冠心病患者血液流变学的影响。方法选取2017年1月-2018年5月期间在本院治疗的82例冠心病患者,随机分为对照组和观察组,各41例。对照组采用缬沙坦治疗,观察组在对照组基础上增加美托洛尔治疗,对比分析两组治疗前后血液流变学指标。结果观察组全血高切粘度(3.95±1.02)mPa/s、全血低切粘度(6.36±1.02)mPa/s、血浆粘度(1.23±0.34)mPa/s、细胞聚集指数(1.26±0.56)、纤维蛋白原(3.04±1.02)g/L显著低于对照组[(4.45±1.32)mPa/s、(7.31±1.34)mPa/s、(1.38±0.29)mPa/s、(1.86±0.52)、(4.03±0.98)g/L)],组间差异具有统计学意义(P<0.05)。结论冠心病患者采用缬沙坦与美托洛尔联合治疗,可有效改善血液流变学,有助于改善患者预后。

Objective To investigate the effect of valsartan combined with metoprolol on hemorheology in patients with coronary heart disease.Methods82patients with coronary heart disease(CHD)treated in our hospital from January2017to May2018were randomly divided into control group and observation group,with41cases in each group.The control group was treated with valsartan,and the observation group was treated with metoprolol on the basis of the control group.The hemorheological indexes of the two groups before and after treatment were compared and analyzed.Results The whole blood high shear viscosity(3.95±1.02)mPa/s,whole blood low shear viscosity(6.36±1.02)mPa/s,plasma viscosity(1.23±0.34)mPa/s,cell aggregation index(1.26+0.56),fibrinogen(3.04±1.02)g/L in the observation group were significantly lower than those in the control group[(4.45±1.32)mPa/s,(7.31±1.34)mPa/s,(1.38±0.29)mPa/s,(1.86±0.52),(4.03±0.98)g/L],and the difference between groups was statistically significant(P<0.05).Conclusion The combination of valsartan and metoprolol can effectively improve the hemorheology and prognosis of patients with coronary heart disease.